Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 2014 Apr;19(4):426-8
Date
03/29/2014Pubmed ID
24668327Pubmed Central ID
PMC3983812DOI
10.1634/theoncologist.2013-0231Scopus ID
2-s2.0-84898429501 (requires institutional sign-in at Scopus site) 11 CitationsAbstract
Mucositis may limit the therapeutic window for mammalian target of rapamycin inhibitor-based combination therapy, necessitating treatment interruptions and/or dose reductions. Optimizing treatment or prophylactic interventions for mucositis will enable patients to continue effective treatment while maintaining good quality of life.
Author List
Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing AAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Male
Metformin
Middle Aged
Mucositis
Niacinamide
Protein Kinase Inhibitors
Retrospective Studies
Sirolimus
TOR Serine-Threonine Kinases
Treatment Outcome
Young Adult